| Date | Title | Description |
| 10.12.2025 | Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006 | HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals") and Formation Bio today announced Formation Bio's acquisition of worldwide r... |
| 10.07.2024 | Formation Bio: AI-Native Pharma Company Secures $372 Million In Series D Funding | AI-native pharma company Formation Bio announced that it has raised $372 million of Series D funding. This funding round was led by a16z, with significant participation from Sanofi. Current investors, including Sequoia, Thrive, Emerson Coll... |
| 27.06.2024 | Formation Bio: Revolutionizing Pharma with AI | Formation Bio, a NYC-based tech-driven and AI-native pharma company, recently secured a staggering $372M in Series D funding. This funding, led by a16z and with significant participation from Sanofi, marks a significant milestone for the co... |
| 26.06.2024 | Formation Bio secures $372MM Series D funding to grow drug pipeline and continue expanding AI-driven drug development platform | NEW YORK, June 26, 2024 /PRNewswire/ -- Formation Bio, a tech-driven and AI-native pharma company, announced today that it has raised $372MM of Series D financing. The financing was led by a16z with significant participation from Sanofi. Cu... |
| 26.06.2024 | Formation Bio Raises $372M in Series D Funding | Formation Bio, a NYC-based tech-driven and AI-native pharma company, raised $372M in Series D funding.
The round was led by a16z with participation from Sanofi, Sequoia, Thrive, Emerson Collective, and Lachy Groom, along with new investors,... |
| 26.06.2024 | AI-powered drug development startup Formation Bio raises $372M
Your vote of support is important to us and it helps us keep the content FREE.
One click below supports our mission to provide free, deep... | Formation Bio Inc., a startup using artificial intelligence to speed up drug development, today announced that it has closed a mammoth $372 million investment.
Andreessen Horowitz led the Series D funding round. It was joined by pharmaceuti... |
